Skip to content

Study · Randomized controlled trial · n = 84 · 2021

5 results

Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.

Yammine L, Green CE, Kosten TR, de Dios C, Suchting R, Lane SD, Verrico CD, Schmitz JM

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco1 Aug 2021Cited by 100 (Europe PMC)

PMID33831213 (opens in a new tab)PMCIDPMC8517504 (opens in a new tab)DOI10.1093/ntr/ntab066 (opens in a new tab)PepBankPUB-33831213
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Among abstinent smokers receiving nicotine patches, post-cessation weight was lower with exenatide than placebo.

    In plain wordsAmong abstinent smokers receiving nicotine patches, body weight was lower with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePost-cessation body weight
    Study

    n: not reported in source

    Comparator
    Placebo plus nicotine patch
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    Weight difference
    5.6 pounds
    lower with exenatide versus placebo

    Source sentences

    Summary
    Post-cessation body weight was 5.6 pounds lower in the exenatide group compared to placebo (PP = 97.4%).
    4 context sentences
    Summary · context
    Exenatide, in combination with the NRT improved smoking abstinence, reduced craving and withdrawal symptoms, and decreased weight gain among abstainers.
    Summary · context
    Eighty-four prediabetic and/or overweight smokers were randomized (1 : 1) to once-weekly placebo or exenatide, 2 mg, subcutaneously.
    Summary · context
    All participants received NRT (21 mg) and brief smoking cessation counseling.
    Summary · context
    Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In prediabetic or overweight smokers receiving nicotine patches, exenatide increased smoking abstinence versus placebo.

    In plain wordsIn smokers receiving nicotine patches, exenatide increased smoking abstinence compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSmoking abstinence
    Study

    n = 84

    Comparator
    Placebo plus nicotine patch
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    Abstinence
    46.3%
    exenatide
    Abstinence
    26.8%
    placebo
    Risk ratio
    1.7 risk ratio
    exenatide vs placebo; 95% credible interval 0.96 to 3.27

    Source sentences

    Summary
    Exenatide increased the risk for smoking abstinence compared to placebo (46.3% and 26.8%, respectively), (risk ratio [RR] = 1.70; 95% credible interval = [0.96, 3.27]; PP = 96.5%).
    3 context sentences
    Summary · context
    Eighty-four prediabetic and/or overweight smokers were randomized (1 : 1) to once-weekly placebo or exenatide, 2 mg, subcutaneously.
    Summary · context
    All participants received NRT (21 mg) and brief smoking cessation counseling.
    Summary · context
    Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In smokers receiving nicotine patches, exenatide reduced end-of-treatment craving versus placebo.

    In plain wordsIn smokers receiving nicotine patches, exenatide reduced craving compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCraving
    Study

    n = 84

    Comparator
    Placebo plus nicotine patch
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Exenatide reduced end-of-treatment craving in the overall sample and withdrawal among abstainers.
    3 context sentences
    Summary · context
    Eighty-four prediabetic and/or overweight smokers were randomized (1 : 1) to once-weekly placebo or exenatide, 2 mg, subcutaneously.
    Summary · context
    All participants received NRT (21 mg) and brief smoking cessation counseling.
    Summary · context
    Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.
  4. 04HumanRandomized controlled trialSafety outcome

    In smokers receiving nicotine patches, adverse events were reported more frequently with exenatide than placebo.

    In plain wordsIn smokers receiving nicotine patches, reported adverse events were more frequent with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdverse events
    Study

    n = 84

    Comparator
    Placebo plus nicotine patch
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    Adverse events
    9.5%
    exenatide
    Adverse events
    2.3%
    placebo

    Source sentences

    Summary
    Adverse events were reported in 9.5% and 2.3% of participants in the exenatide and placebo groups, respectively.
    3 context sentences
    Summary · context
    Eighty-four prediabetic and/or overweight smokers were randomized (1 : 1) to once-weekly placebo or exenatide, 2 mg, subcutaneously.
    Summary · context
    All participants received NRT (21 mg) and brief smoking cessation counseling.
    Summary · context
    Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    Among abstinent smokers receiving nicotine patches, exenatide reduced withdrawal versus placebo.

    In plain wordsAmong abstinent smokers receiving nicotine patches, exenatide reduced withdrawal compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWithdrawal among abstainers
    Study

    n: not reported in source

    Comparator
    Placebo plus nicotine patch
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    2 mg once weekly · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Exenatide reduced end-of-treatment craving in the overall sample and withdrawal among abstainers.
    3 context sentences
    Summary · context
    Eighty-four prediabetic and/or overweight smokers were randomized (1 : 1) to once-weekly placebo or exenatide, 2 mg, subcutaneously.
    Summary · context
    All participants received NRT (21 mg) and brief smoking cessation counseling.
    Summary · context
    Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2Results postedNCT02975297

Exenatide Once Weekly for Smoking Cessation

The University of Texas Health Science Center, Houstonn = 84Jul 2016 to 3 Jan 2020

Smoking Cessation

Trial pageClinicalTrials.govUpdated 28 Jan 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.